{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+Saline+Infusion+%28Albumin+placebo%29", "query": { "intervention": "Intravenous Saline Infusion (Albumin placebo)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-06T17:01:58.409Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06052176", "title": "Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cirrhosis", "Hepatic Encephalopathy" ], "interventions": [ { "name": "Albumin Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hunter Holmes Mcguire Veteran Affairs Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-11-02", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-06T17:01:58.409Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06052176" }, { "nct_id": "NCT00949663", "title": "Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Glucose-dependent Insulinotropic Polypeptide (GIP)", "type": "DRUG" }, { "name": "Xenin-25", "type": "DRUG" }, { "name": "Glucose-dependent Insulinotropic Polypeptide plus Xenin-25", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 38, "start_date": "2009-10", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2014-07-22", "last_synced_at": "2026-10-06T17:01:58.409Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949663" }, { "nct_id": "NCT01845441", "title": "Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stroke", "Brain Ischemia", "Vasospasm, Intracranial", "Hemorrhage, Intracranial" ], "interventions": [ { "name": "Dexmedetomidine", "type": "DRUG" }, { "name": "Fentanyl", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University Hospitals Cleveland Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 7, "start_date": "2012-04", "completion_date": "2021-12", "has_results": true, "last_update_posted_date": "2022-12-28", "last_synced_at": "2026-10-06T17:01:58.409Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01845441" }, { "nct_id": "NCT01951729", "title": "The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pre-diabetes" ], "interventions": [ { "name": "Control", "type": "DRUG" }, { "name": "Xenin-25 without atropine", "type": "DRUG" }, { "name": "GIP without atropine", "type": "DRUG" }, { "name": "Placebo with atropine", "type": "DRUG" }, { "name": "Xenin-25 with atropine", "type": "DRUG" }, { "name": "GIP with atropine", "type": "DRUG" }, { "name": "GIP plus Xenin-25 without atropine", "type": "DRUG" }, { "name": "GIP plus Xenin-25 with atropine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2013-03-13", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2018-05-25", "last_synced_at": "2026-10-06T17:01:58.409Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951729" }, { "nct_id": "NCT00798915", "title": "Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Glucose-dependent Insulinotropic Polypeptide (GIP)", "type": "DRUG" }, { "name": "Xenin-25", "type": "DRUG" }, { "name": "Glucose-dependent Insulinotropic Polypeptide plus Xenin-25", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2008-12", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2018-05-03", "last_synced_at": "2026-10-06T17:01:58.409Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00798915" }, { "nct_id": "NCT01951716", "title": "Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Does the Vagus Nerve Mediate the Effects of Xenin-25" ], "interventions": [ { "name": "Graded Glucose Infusion with Placebo", "type": "DRUG" }, { "name": "Graded Glucose Infusion with GIP Alone", "type": "DRUG" }, { "name": "Graded Glucose Infusion with xenin-25 alone", "type": "DRUG" }, { "name": "Graded Glucose Infusion with GIP plus xenin-25", "type": "DRUG" }, { "name": "Meal Tolerance Test with Placebo", "type": "DRUG" }, { "name": "Meal Tolerance Test with xenin-25", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2013-01", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2018-04-26", "last_synced_at": "2026-10-06T17:01:58.409Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951716" }, { "nct_id": "NCT00220740", "title": "Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating" ], "interventions": [ { "name": "Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified", "type": "DRUG" }, { "name": "Albumin (Human) 25%, United States Pharmacopeia (USP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2004-04", "completion_date": "2006-06", "has_results": true, "last_update_posted_date": "2016-03-23", "last_synced_at": "2026-10-06T17:01:58.409Z", "location_count": 6, "location_summary": "New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00220740" }, { "nct_id": "NCT03585257", "title": "HEAL STUDY (Hepatic Encephalopathy and Albumin Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cirrhosis", "Hepatic Encephalopathy", "Minimal Hepatic Encephalopathy", "Covert Hepatic Encephalopathy" ], "interventions": [ { "name": "25% IV albumin", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Hunter Holmes Mcguire Veteran Affairs Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2018-06-20", "completion_date": "2022-03-30", "has_results": false, "last_update_posted_date": "2022-05-31", "last_synced_at": "2026-10-06T17:01:58.409Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03585257" }, { "nct_id": "NCT04895358", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "liposomal doxorubicin", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "normal saline", "type": "DRUG" }, { "name": "dextrose", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 342, "start_date": "2021-06-18", "completion_date": "2027-12-18", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-06T17:01:58.409Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Monterey", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895358" }, { "nct_id": "NCT00108355", "title": "Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ascites", "Cirrhosis" ], "interventions": [ { "name": "Albumin", "type": "DRUG" }, { "name": "Intravenous Saline Infusion (Albumin placebo)", "type": "DRUG" }, { "name": "Midodrine", "type": "DRUG" }, { "name": "Oral tablet (Midodrine placebo)", "type": "DRUG" }, { "name": "Octreotide LAR", "type": "DRUG" }, { "name": "Saline injection (Octreotide LAR placebo)", "type": "DRUG" }, { "name": "Large Volume Paracentesis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 29, "start_date": "2003-12", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-03-06", "last_synced_at": "2026-10-06T17:01:58.409Z", "location_count": 1, "location_summary": "West Haven, Connecticut", "locations": [ { "city": "West Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00108355" } ] }